2024-11-17 13:45:32
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Corporate/ 2023-07-23
CStone's anti-PD-L1 antibody demons...

SUZHOU,China,Dec. 10,2019-- CStone Pharmaceuticals ("CStone" or the "Company",HKEX: 2616) updated results from the CS100...

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Corporate/ 2023-07-23
Results of Fully-human BCMA CAR-T for th...

SUZHOU,China,Dec. 10,2019-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical company that develo...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release